Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT05721001 (NEO) for Vascular Aneurysm is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
French Registry Conducted on E-vita OPEN NEO
Primary objective is evaluation of in-hospital all-cause mortality after treatment of extensive acute and chronic aortic pathologies with E-vita OPEN NEO.
Primary objective:
• Evaluation of in-hospital all-cause mortality after treatment of extensive acute and chronic aortic pathologies with E-vita OPEN NEO
Secondary objective:
• Evaluation of the morbi-mortality in-hospital, 1 year and 3 years follow-up after treatment of extensive acute and chronic aortic pathologies with E-vita OPEN NEO.
Morbidity is defined as:
- new permanent (> 30 days) neurological complications (stroke mRS > 2, spinal cord ischemia, paraparesis, paraplegia)
- new clinical malperfusion (including visceral malperfusion)
- new permanent (>90 days) renal insufficiency requiring dialysis or hemofiltration in patients with normal pre-procedure serum creatinine level The others secondary objectives are to assess changes of the stent graft system in the medium (1 year) and long term (3 years):
- type Ib, II, or IV endoleaks in patients with aneurysm or type Ib or II entry flow in patients with dissection
- permeability of the vascular part
Patient population All patients treated with E-vita OPEN NEO until 31st March 2024 will be included in this registry if they are not opposed to the study. Follow-up of these patients will end in 2027.
Patients to be documented:
All male and female patients who have undergone implantation of E-vita OPEN NEO at their physician's discretion in France since device CE marking in 2020 and until 31st March 2024.
Inclusion/Exclusion Criteria None Indications for Use for E-vita OPEN NEO are listed in the device IFU. Patients are treated with E-vita OPEN NEO at the discretion of the treating physician.
Methodology In this study, we will conduct an observational cohort of consecutive patients who receive / received an E-vita OPEN NEO implant for the treatment of extensive acute or chronic aortic pathologies until 31st March, 2024. Participating physicians will be asked to provide their observations collected during routine care for patients he/she had decided to treat with E-vita OPEN NEO. All patients will be provided with a non-objection letter and given the opportunity to refuse to participate. Patients will either receive the non-objection letter before treatment or it is mailed to them by their treating physician.
A screening log will be kept during the study. In the screening log it will be documented which patients objected to the collection of their data and were therefore not included in the registry. The number of E-vita OPEN NEO implanted in France during the enrolment phase of the study will be submitted and compared to the number of patients enrolled in the study to assess the coverage of the study.
Patient data will be documented at the following time points: Pre-operative planning, intervention, prior to discharge from hospital, 1 year, and 3 years follow-up. The period of data collection will be 3 years ± 6 months (depending on the time point of the 3 years follow-up visit) starting from the intervention for each patient. All adverse events defined prior to study start will be adjudicated by the Clinical Event Committee (CEC).
Inclusion period (retrospective/prospective): Q3 2022 till Q1 2024 Follow-up: 3 years Total study period: 6 years
NEO - E-vita Open Neo Treatment of Aortic Arch Aneurysms and Dissections
- NEO
Aorta
Aneurysm
Dissection
Open
Repair
Frozen
Elephant
Trunk
| Participant Group/Arm | Intervention/Treatment |
|---|---|
N/A | Surgical Repair In Frozen Elephant Trunk procedure, the proximal aortic arch is replaced with a dacron graft, and a thoracic stent graft, sutured to the distal end of the dacron prosthesis, is deployed antegradely into the descending aorta. This mostly one-stage alternative approach eliminates the interval mortality rate related to the conventional elephant trunk procedure. Moreover, it constitutes a solution in fragile patients who cannot safely complete a second major operation after surviving the first. |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Mortality | Rate of in-hospital all-cause mortality | through study completion, an average of 3 years |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Mortality | All-cause mortality | 1 year and 3 years |
Morbidity | new neurological complication (defined as stroke, spinal cord ischemia, paraparesis, paraplegia), new clinical malperfusion (including visceral malperfusion), new permanent (\> 90 days) renal insufficiency requiring dialysis or hemofiltration in patients with normal pre-procedure serum creatinine level | 1 year and 3 year |
Severe Adverse Events | Rate of patients with SAE until 1 year follow-up (device-related, procedure-related, disease-related) | 1 year |
Severe Adverse Events | Rate of patients with SAE between 1 year and 3 year year follow-up (device-related, procedure-related, disease-related) | 3 years |
Neurological complications | Rate of patients with New permanent (\> 30 days) neurological complications | At discharge, an average of 45 days, 1 year, 3 years |
Neurological complications | Rate of patients with New transient (≤ 30 days) neurological complications | At discharge, an average of 45 days, 1 year, 3 years |
Stroke | New permanent (\> 30 days) stroke | At discharge, an average of 45 days, 1 year, 3 years |
Stroke | Rate of patients with New transient (≤ 30 days) stroke | At discharge, an average of 45 days, 1 year, 3 years |
Paraplegia | Rate of patients with New permanent (\> 30 days) paraplegia | At discharge, an average of 45 days, 1 year, 3 years |
Paraparesis | Rate of patients with New permanent (\> 30 days) paraparesis | At discharge, an average of 45 days, 1 year, 3 years |
Paraparesis | Rate of patients with New transient (≤ 30 days) paraparesis | At discharge, an average of 45 days, 1 year, 3 years |
Malperfusion | Rate of patients with New clinical visceral malperfusion | At discharge, an average of 45 days, 1 year, 3 years |
Renal Insufficiency | Rate of patients with New transient (≤ 90 days) renal insufficiency requiring dialysis or hemofiltration | At discharge, an average of 45 days, 1 year, 3 years |
Renal Insufficiency | Rate of patients with New permanent (\> 90 days) renal insufficiency requiring dialysis or hemofiltration | At discharge, an average of 45 days, 1 year, 3 years |
Permeability | Rate of patients with Permeability of the vascular part | 1 year, 3 years |
Reinterventions | Rate of patients with Reinterventions (device-related, procedure-related, disease-related) | 1 year, 3 years |
Additional interventions | Rate of patients with Unplanned / planned additional interventions | 1 year, 3 year |
Bleeding | Re-exploration due to bleeding | At discharge, an average of 45 days, 1 year, 3 years |
Endoleaks | Rate of patients with Endoleak type Ib, II, III or IV | At discharge, an average of 45 days, 1 year, 3 years |
False Lumen | Rate of patients with Obliterated, completely thrombosed, partially thrombosed, or patent false lumen in the stented region | At discharge, an average of 45 days, 1 year, 3 year |
Entry flow | Rate of patients with Type Ib, II or R entry flow, endoleak of unknown origin | At discharge, an average of 45 days, 1 year, 3 year |
- non-objection from the patient for data collection within this Registry
- patient treated with E-vita Open NEO
- objection from the patient for data collection within this Registry
JOTEC GmbHICON plc